摘要
随着分子生物学研究的深入,肿瘤靶向治疗的研究和临床应用取得了突破性进展。HER-2基因在乳腺癌诊断、治疗及评价预后中具有重要指导价值。本文围绕HER-2阳性乳腺癌患者的抗HER-2靶向药物及个体化治疗治疗做一综述。
With the deepening of molecular biology research, breakthroughs have been made in the research and clinical application of tumor targeted therapy. The HER-2 gene has important guiding value in the diagnosis, treatment and evaluation of prognosis of breast cancer. This article reviews the anti-HER-2 targeting drugs and individualized treatment of HER-2 positive breast cancer patients.
引文
[1]Harari D,Yarden Y.Molecular mechanisms underlying ErbB2/HER2 action in breast cancer[J].Oncogene,2000,19(53):6102-6114.
[2]Au HJ,Eiermann W,Rnbert NJ,et al.Health-related quality of life with adjuvant doeetaxel-and trastuzumab-based regimens in patients with node-positive and high-risk node-negative,HER2-positive early breast cancer:Results from the BCIRG006 study[J].Oncologist,2013,18(7):812-818.
[3]Perez EA,Press MF,Dueck AC,et al.Immunohistochemistry and fluorescence in situ hybridization assessment of her 2 in clinical trials of adjuvant therapy for breast cancer(NCCTG N9831,Bcirg006,And bcirg005)[J].Breast Cancer Res Treat,2013,138(1):99-108.
[4]Perez EA,Romond EH,Smnan VJ,et al.Four-year follow-up of trastuzumab plus adjuvant chemntherapy for operable human epidermal growth factor receptor 2-positive breast cancer:Joint analysis of data from NCCTG N9831 and NSABP B-31[J].J Clin Oncol,2011,29(25):3366-3373.
[5]Cameron D,Piccart-Gebhart MJ,Gelber RD,et al.11 years'follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer:final analysis of the HER ceptin Adjuvant(HERA)trial[J].Lancet,2017,389(10075):1195-1205.
[6]Purmnnen TT,Pankalainen E,Tururunen JH,et al.Shortcouse adjuvant trastuzunmab therapy in early stage breast cancer in Finland Cost-effectiveness and value of information analysis based on the 5-year follow-up results of the fin her trial[J].Aeta Oncologica,2011,50(3):344-352.
[7]Baselga J,Gelmon KA,Verma S,et al.PhaseⅡtrial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy[J].J Clin Oncol,2010,28(7):1138-1144.
[8]Swain SM,Baselga J,Miles D,et al.Incidence of central nervous system metastases in patients with HER-2-positive metastatic breast cancer treated with pertuzumab, Trastuzumab, And docetaxel:results from the randomized phase iii study cleopatra[J].Ann Oncol,2014,25(6):1116-1121.
[9]Wildiers H,Tryfonidis K,Lago LD,et al.Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer(EORTC 75111-10114):an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group[J].Lancet Oncol,2018,19(3):323-336.
[10]Gianni L,Pienkowski T,Im YH,et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast caneer(NeoSphere):arandomised multicentre,open-label,phase 2 trial[J].Lancet Oncol,2012,13(1):25-32.
[11]Welslau M,Diéras V,Sohn JH,et al.Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine(T-DM1)versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer[J].Cancer,2014,120(5):642-651.
[12]Ellis PA,Barrios CH,Eiermann W,et al.PhaseⅢ,randomized studyof trastuzumab emtansine(T-DMI)+pertuzumab(P)vs trastuzumab+taxane(HT)for first-line treatment of HER2-positive MBC:primary results from the MARIANNE study[J].J Clin Oncol,2015,33(supp1):507.
[13]Krop IE,Kim SB,González-Martín A,et al.Trastuzumab emtansine versus treatment of physician's choice for pretreated her-2-positive advanced breast cancer(TH3resa):a randomised,Open-label,Phase 3 trial[J].Lancet Oncol,2014,15(7):689-699.
[14]JoséBaselga,Ian Bradbury,Holger Eidtmann,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):a randomised, open-label, multicentre, phase 3trial[J].Lancet Oncol,2012,379(9816):633-640.
[15]Michael Untch,Sibylle Loibl,Joachim Bischoff,et al.Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy(GeparQuinto, GBG 44):a randomised phase 3 trial[J].Lancet Oncol,2012,13(2):135-144.
[16]Burstein HT,Sun Y,Dirix LY,et al.Neratinib, Anirrenersible erbb receptortyrosine kinase inhibitor,In patients with advanced erbb positive breast cancer[J].Journal of Clinical Oncology,2010,28(8):1301-1307.
[17]Canonici A1,Gijsen M,Mullooly M,et al.Neratinib overcomes trastuzumab resistance in her 2 amplified breast cancer[J].Oncotarget,2013,4(10):1592-1605.
[18]Chan A,Delaloge S,Holmes FA,et al.Neratinib after trastuzumab-based adjuvant therapy in patients with HER-2positive breast cheer(ExteNET):a muhicentre, randomised,double-blind, placebo-controlled, phase 3 trial[J].Lancet Oncol,2016,17(3):367-377.
[19]Martin M,Holmes FA,Ejlertsen B,et al.Neratinib after trastuzumab-based adjuvant therapy in HER-2 positive breast cancer(ExteNET):5-year analysis of a randomised,doubleblind, placebo-controlled,phase 3 trim[J].The Lancet Oncology,2017,18(12):1688-1700.
[20]Paik S,Kim C,Wolmark N.HER2 status and benefit from adjurant trastuzumab in breast cancer[J].N Engl J Med,2008,358(13):1409-1411.
[21]Fehrenbacher L.Adjuvant trastuzumab did not improve outcomes for patients with her2-low breast cancer:2017 San Antonio Breast Cancer Symposium[C].San Antonio,2017,Abstract:GS1-02.
[22]Cameron D,Piccart-Gebhart MJ,Gelber RD,et al.11 years'follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer:final analysis of the HERceptin Adjuvant(HERA)trial[J].Lancet,2017,389(10075):1195-1205.
[23]Pivot X,Romieu G,Debled M,et al.6 months versus 12months of adjuvant trastuzumab for patients with HER2-positive early breast cancer(PHARE):a randomised phase 3 trial[J].Lancet Oncol,2013,14(8):741-748.
[24]Pivot X,Suter T,Nabholtz JM,et al.Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phaseⅢstudy[J].Eur J Cancer,2015,51(13):1660-1666.
[25]Earl H,Cameron D,Miles D,et al.PERSEPHONE is a randomised phaseⅢcontrolled trial comparing six months of trastuzumab to the standard 12 months in patients with HER2positive early breast cancer[J].European Journal of Surgical Oncology,2014,40(5):619.
[26]Conte PF,Bisagni G,Frassoldati A,et al.9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy:Results of the phaseⅢmuhieentrie Italian study Short-HER[J].Clin Oncol,2017,35(15_suppl):501.
[27]Chavez-MacGregor M,A Mittendorf E.Extended adjuvant therapy in patients with HER2-positive breast cancer:some answers, even more questions[J].Lancet Oncol,2017,18(12):1568-1569.
[28]Blackwell KL,Burstein HJ,Storniolo AM,et al.Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor2-positive metastatic breast cancer:final results from the egf 104900study[J].Clin Oncol,2012,30(21):2585-2592.
[29]de Azambuja E,Holmes AP,Pieeart-Gebhart M,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO):survival outcomes of a randomised,open-label,multieentre,phase 3 trial and their association with pathological complete response[J].Lancet Oncol,2014,15(10):1137-1146.
[30]Krop IE,Hillman D,Polley MY,et al.Invasive disease-free survival and gene expression signatures in CALGB(Alliance)40601, a randomized phaseⅢneoadjuvant trial of dual HER2-targeting with lapatinib added to chemotherapy plus trastuzumab[J].Cancer Research,2018,78(4).
[31]AndréRobidoux MD,Tang G,Rastogi P,et al.Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer(NSABP protocol B-41):an open-label, randomised phase 3 trial[J].Lancet Oncol,2013,14(12):1183-1192.
[32]Broglio KR,Quintana M,Foster M,et al.Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes:a meta-analysis[J].JAMA Oncol,2016(2):751-760.
[33]Loibl S,Gianni L.HER2-positive breast cancer[J].The Lancet,2017,389(10087):2415-2429.
[34]Puglisi F,Fontanella C,Amoroso V,et al.Current challenges in HER2-positive breast cancer[J].Critical Reviews in Oncology/Hematology,2016,98(11):211-221.
